Optimization of the cut-offs in acetylcholine receptor antibodies and diagnostic performance in myasthenia gravis patients

被引:6
|
作者
Shao, Kai [1 ]
Yue, Yao-Xian [2 ]
Zhao, Li-Ming [3 ]
Hao, Hong-Jun [4 ]
Ding, Xiao-Jun [5 ]
Jiang, Ping [6 ]
Yan, Chuan-Zhu [1 ,2 ]
Li, Hai-Feng [2 ,6 ]
机构
[1] Shandong Univ, Qilu Hosp Qingdao, Cheeloo Coll Med, Dept Cent Lab, Qingdao, Peoples R China
[2] Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Neurol, Jinan, Peoples R China
[3] Linyi Peoples Hosp, Dept Nucl Med, Linyi, Peoples R China
[4] Peking Univ First Hosp, Lab Neuroimmunol, Beijing, Peoples R China
[5] Shandong Univ, Qilu Hosp Qingdao, Cheeloo Coll Med, Dept Neurol, Qingdao, Peoples R China
[6] Capital Med Univ, Xuanwu Hosp, Dept Neurol, Beijing, Peoples R China
基金
中国国家自然科学基金;
关键词
Acetylcholine receptor antibody; Cut; -off; Myasthenia gravis; Diagnostic performance; Agreement; OPTICA SPECTRUM DISORDER; ASSAY; AUTOANTIBODIES; TITERS;
D O I
10.1016/j.cca.2022.06.017
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Objective: This study aims to establish an optimization procedure to define the cut-offs of quantitative assays for acetylcholine receptor antibody (AChRAb), evaluate their diagnostic performance in myasthenia gravis (MG), and explore the association with clinical features. Methods: Samples from a representative cohort of 77 MG patients, 80 healthy controls (HC) and 80 other autoimmune diseases (OAD) patients were tested using competitive inhibition ELISA and RIA. Raw values (OD and cpm) and processed values (inhibition rate, binding rate and concentration) were used to define the cut-offs with statistical methods, a rough method, and receiver operating characteristic (ROC) curve. Optimal cut-offs were selected by comparing false positive rates in HC and OAD individuals. The diagnostic performance was evaluated in whole MG cohort and subgroups. Agreement between ELISA and RIA for AChRAb positivity were examined with Kappa test and McNemar test. Clinical association with AChRAb was explored by comparison among subgroups and with Spearman rank correlation. Results: The optimal cut-offs for AChRAb positivity were determined as OD <= 1.79 for ELISA and cpm > 1234.12 for RIA, which derived from statistical method and performed better than those derived from ROC curves. The sensitivity and specificity were 74.03%, 100% for ELISA, and 74.03%, 99.37% for RIA. There was good agreement between ELISA and RIA for AChRAb positivity in whole cohort and subgroups (weighted k > 0.71, p < 0.01; McNemar test, p > 0.05). Levels of AChRAb were different in MG subgroups (p < 0.01). Correlation between Quantitative Myasthenia Gravis scores and AChRAb levels was moderate for ELISA and RIA (rs = -0.60 and 0.57, p < 0.01). Conclusion: The raw testing values of ELISA and RIA were found as optimal quantitative measures of AChRAb levels. There are good agreements on diagnostic performance between two assays. Quantitative values are more informative than positivity in association with clinical features.
引用
收藏
页码:122 / 130
页数:9
相关论文
共 50 条
  • [41] Performance of cut-offs adjusted with positive control band intensity in line-blot assays for myositis-specific antibodies
    Chang, Sung Hae
    Choi, Se Rim
    Choi, Yong Seok
    Go, Dong Jin
    Park, Jun Won
    Ha, You-Jung
    Park, Jin Kyun
    Kang, Eun Ha
    Lee, Eun Young
    Shin, Kichul
    Lee, Eun Bong
    Song, Yeong Wook
    Lee, Yun Jong
    RHEUMATOLOGY INTERNATIONAL, 2023, 43 (08) : 1507 - 1513
  • [42] INHIBITION OF MYOSIN ATPASE ACTIVITY BY HUMAN MYASTHENIA-GRAVIS ANTIBODIES REACTIVE WITH THE ACETYLCHOLINE-RECEPTOR
    MOHAN, S
    KROLICK, KA
    FEBS LETTERS, 1993, 318 (01) : 50 - 52
  • [43] Rethinking the utility of acetylcholine receptor antibody titer as a pharmacodynamic biomarker for myasthenia gravis
    Lee, Ikjae
    Sanders, Donald
    MUSCLE & NERVE, 2021, 64 (04) : 385 - 387
  • [44] Efgartigimod for generalized myasthenia gravis with or without anti-acetylcholine receptor antibodies: a worldwide and Japanese perspective
    Suzuki, Shigeaki
    Uzawa, Akiyuki
    Murai, Hiroyuki
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2022, 18 (12) : 1207 - 1215
  • [45] IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis
    Leite, Maria Isabel
    Jacob, Saiju
    Viegas, Stuart
    Cossins, Judy
    Clover, Linda
    Morgan, B. Paul
    Beeson, David
    Willcox, Nick
    Vincent, Angela
    BRAIN, 2008, 131 : 1940 - 1952
  • [46] Myasthenia gravis patients, but not healthy subjects, recognize epitopes that are unique to the ε-subunit of the acetylcholine receptor
    Ragheb, S
    Mohamed, M
    Lisak, RP
    JOURNAL OF NEUROIMMUNOLOGY, 2005, 159 (1-2) : 137 - 145
  • [47] Interventional Effect of Jianpi Bushen Granule Combined with Western Medicine on the Level of Serum Acetylcholine Receptor Antibodies in Myasthenia Gravis Patients
    Chao Jiang
    Ping Liu
    Jing-Sheng Zhang
    Wen-Jing Bao
    Yan Liang
    Shao-Bo Qiu
    Lin Jiang
    WorldJournalofTraditionalChineseMedicine, 2015, 1 (04) : 42 - 47
  • [48] False-positive acetylcholine receptor antibody results in patients without myasthenia gravis
    Maddison, Paul
    Sadalage, Girija
    Ambrose, Philip Alexander
    Jacob, Saiju
    Vincent, Angela
    JOURNAL OF NEUROIMMUNOLOGY, 2019, 332 : 69 - 72
  • [49] Ryanodine receptor antibodies are associated with severe myasthenia gravis
    Skeie, GO
    Bartoccioni, E
    Evoli, A
    Aarli, JA
    Gilhus, NE
    EUROPEAN JOURNAL OF NEUROLOGY, 1996, 3 (02) : 136 - 140
  • [50] Immune profiling beyond antibodies in double seronegative and acetylcholine receptor antibody positive myasthenia gravis: What do we learn?
    Kushlaf, Hani
    MUSCLE & NERVE, 2021, 63 (04) : 439 - 441